PA5-55452

antibody from Invitrogen Antibodies

Targeting: SLC25A26

Immunohistochemistry

Antibody data

Submit

Validation data

Product number: PA5-55452 - Provider product page
Provider: Invitrogen Antibodies
Product name: SLC25A26 Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Recombinant full-length protein
Description: Immunogen sequence: SAGEVVACLI RVPSEVVKQR AQVSASTRTF QIFSNILYEE GIQGLYRGYK STVLREIPFS LVQFPLWESL KALWSWRQDH VVDSWQSAVC GAFAGGFAAA VTTPLDVAKT RITLAKAGSS TADGNVLSVL HGV Highest antigen sequence identity to the following orthologs: Mouse - 89%, Rat - 89%.
Reactivity: Human
Host: Rabbit
Isotype: IgG
Vial size: 100 µL
Concentration: 0.10 mg/mL
Storage: Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

SLC25A26 protein structure - PA5-55452 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 3 CTB promoted accumulation of SLC25A26. A Western blots were used to detect the protein expressions of Ki67, HMGA1, and SLC25A26 in liver cancer tissues and adjacent tissues from five pairs of HCC patients (T: tumor; A: Adjacent); B , C Real-time PCR analyses of Ki67, SLC25A26 and senescent makers in HCC tumor and adjacent tissues; D Typical images of Ki67, HMGA1 and SLC25A26 immunohistochemical staining in HCC tumors and adjacent tissues (scale bar, 50 mum); E The mRNA level of SLC25A26 was detected by real-time PCR. F Western blot analysis was used to determine the expression of SLC25A26. Statistical significance for this graph, data are represented as mean +- S.D. ( n = 5); * P < 0.05 vs. control, ** P < 0.01 vs. control.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 4 Interfering with SLC25A26 weakened the effect of CTB-induced HCC cells senescence. HepG2 cells and Huh-7 cells were incubated with the prescribed concentration of CTB or transfected with SLC25A26 siRNA for 24 h. A , B Western blot was used to analyze the transfection efficiency of siSLC25A26 in both HCC cells; C , D Western blot analyzed the expression of senescent makers; E , F Real-time PCR analyzed the expression of senescent makers; G , H Flow Cytometry analyzed cell cycle to determine the percentage of cell cycle distribution. Statistical significance for this graph, data are represented as mean +- S.D. ( n = 3); * P < 0.05 vs. control, ** P < 0.01 vs. control, *** P < 0.001 vs. control.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 7 CTB repressed tumorigenesis in vivo by regulating SLC25A26. HCC cell line Huh-7 was used to construct subcutaneous xenografts. A Representative images of BALB/c nude mice tumors stripped from different groups ( n = 6); B The body weight change curves of mice in each group during the whole experiment period ( n = 6); C Tumor volume growth curves of mice in each group throughout the experimental period ( n = 6); D Tumor weight was obtained after executing mice on the last day ( n = 6); E Real-time PCR analysis of p16, p21, HMGA1 mRNA levels in tumor tissues; F Western blot was used to analyze the protein expression of p16, p21, HMGA1 in tumor tissues. Representative blots were from three independent experiments; G Immunofluorescence analyses of senescent makers p16, p21, HMGA1 in the tumor tissue; H Elisa kit analyzes SAM levels in the tumor tissue; I Real-time PCR analyses of MAT2A, Ki67 mRNA levels in tumor tissues. J Western blot was used to analyze the protein expression of MAT2A, SLC25A26, Ki67 in tumor tissues. Representative blots were from three independent experiments; K Immunofluorescence analyses of MAT2A, SLC25A26, Ki67 in tumor tissues; Scale bars are 50 mum. Statistical significance for this graph: * P < 0.05 vs. control, ** P < 0.01 vs. control, # P < 0.05 vs. CTB (5 mg/kg) + shSLC25A26, ##P < 0.01 vs. CTB (5 mg/kg) + shSLC25A26.